Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WX-0593 in ALK-positive NSCLC
CTR20212610Phase 2Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of iruplinalkib in ALK-positive non-small cell lung cancer, sponsored by Qilu Pharmaceutical. Started Oct 2021; status: completed.
02
Drugs
iruplinalkib
03
Conditions
ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on CTR20212610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212610.